021-51111890
购物车（0）
sales@molnova.cn
BI 894999
CAS No. 1660117-38-3
BI 894999 ( BI894999 )
产品货号. M12534 CAS No. 1660117-38-3
BI 894999 是一种新型有效的选择性 BET 抑制剂，对 BRD4-BD1 和 BRD4-BD2 溴结构域的 IC50 分别为 5 和 41 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1320 | 有现货 |
|
| 10MG | ￥2130 | 有现货 |
|
| 25MG | ￥4277 | 有现货 |
|
| 50MG | ￥6229 | 有现货 |
|
| 100MG | ￥8748 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称BI 894999
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述BI 894999 是一种新型有效的选择性 BET 抑制剂，对 BRD4-BD1 和 BRD4-BD2 溴结构域的 IC50 分别为 5 和 41 nM。
-
产品描述BI 894999 is a novel potent, selective BET inhibitor with IC50 of 5 and 41 nM for BRD4-BD1 and BRD4-BD2 bromodomains, respectively; displays excellent selectivity over other bromodomains; decreases S-Phase and increases apoptosis, Volasertib augments and prolongs the decrease of MYC expression caused by BI 894999 treatment in AML cell lines; dramatically reduces tumor burden accompanied by eradication of AML cells in mouse bone marrow combined with Volasertib; also represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.Solid Tumors Phase 1 Clinical
-
体外实验——
-
体内实验——
-
同义词BI894999
-
通路Chromatin/Epigenetic
-
靶点Bromodomain
-
受体Bromodomain
-
研究领域Cancer
-
适应症Solid Tumors
化学信息
-
CAS Number1660117-38-3
-
分子量429.524
-
分子式C25H27N5O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 125 mg/mL (291.03 mM)
-
SMILESCN1C(C(C)=CC(C2=NC3=CN=C(C4CCOCC4)C=C3N2[C@@H](C)C5=CC=CC=C5)=N1)=O
-
化学全称(S)-2,4-dimethyl-6-(1-(1-phenylethyl)-6-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)pyridazin-3(2H)-one
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Tontsch-Grunt U, et al. Cancer Lett. 2018 Feb 14;421:112-120.
2. Gerlach D, et al. Oncogene. 2018 Mar 1. doi: 10.1038/s41388-018-0150-2.
